a cure nobody can afford is a demo

a biotech founder told me many cell therapies cost hundreds of thousands per patient. his bet is cells off the shelf. the lesson reaches far past biotech.

share x linkedin facebook

a lone figure with a lantern stands on the left edge of a deep chasm, while a small warm house sits across the gap under a pale sun with no bridge

monday afternoon i taped an episode with a biotech founder working on cell therapy for lung disease. i went in expecting the science. i came out thinking about economics.

he said something blunt in the first few minutes. a lot of today's cell therapies cost hundreds of thousands of dollars per patient, and some cost millions. his view is that you can't treat a chronic disease that millions of people live with at that price. it isn't sustainable, however good the science.

then he explained why it costs so much. many therapies take cells out of the patient and put processed cells back in. he described the patient as someone already worn down by illness and medication, so you're starting with depleted material. the logistics are hard. every batch is custom. it's slow.

his company's bet is the opposite. cells from healthy donors, made to the same standard every time, so a hospital could get them in a week or two instead of building a one-off batch for each person. he called that the gold standard the whole industry is chasing.

i'm not a biologist and i won't pretend to judge the science. the company spent more than a decade on safety and mechanism before getting clearance to start its trial, and the next step is a small safety study. that's the honest stage of the story.

but the business lesson travels to every industry i care about.

a product that works at a price nobody can pay isn't finished. it's a proof of concept. the hard part of many breakthroughs comes after the breakthrough... getting the cost down until normal people can have it.

bitcoin taught me this. the first exchanges i saw were slow and scary for normal users. the network worked from day one. the job was making it usable for someone's mom. robotics is the same right now. lots of robots that work in a demo and cost too much to put in a real warehouse.

he made one more point i liked. he said success in a clinical trial doesn't guarantee success in the real world, because trials exclude many of the sickest patients. so he pays close attention to compassionate use cases, the patients with no other options. that's a founder looking for the hardest customer on purpose, because if it works there, it'll work anywhere.

i also pushed him on something simple. he first answered my question about the next ninety days by describing a normal day. i stopped him and asked again. what happens in the next three months? the answer got sharp. a small trial, a handful of patients, the first two watched for safety before anyone else is dosed. if you're a founder, have that answer ready. the people who might help you want to know what moves next quarter.

long term, i think the next decade belongs to founders who take something rare and make it ordinary. the science creates the possibility. the economics decide who gets to use it.

more on how i think about turning hard technology into a business is in the robotics book.

so what would your product cost if you had to sell it to a million people... and what would you have to change to get there?

share x linkedin facebook
the newsletter

the machine economy brief

one email when it matters: bitcoin, ai, robotics, and what founders should do about it. unsubscribe anytime.

no spam, no list-selling. your email goes to sunny, nowhere else.

want this in your inbox?

the machine economy brief: bitcoin x ai x robotics, once a week.

join the machine economy brief →